Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 09 May 2018
At a glance
- Drugs Lapatinib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics; Pharmacogenomic
- 31 Aug 2018 Biomarkers information updated
- 02 May 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
- 06 Jun 2017 Results (n=23) comparing transcriptome and kinome profiles before and after treatment with FDA-approved anti-HER2 drugs and combinations, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.